Aignostics
Key Facts
| Invested since | 2020 |
| Based in | Brandenburg |
About the company
Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary “Explainable AI” platform draws on research from Fraunhofer Society, Charité, and TU Berlin to overcome the typical “black-box” problem of AI in pathology. Aignostics’ focus lies on developing bespoke AI models for clinical trials and CDx development.
Do you want to
know more about this company?
Aignostics in the news
More startups from Life Sciences
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and …
To the complete profileof Nebula Biocides
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
To the complete profileof Cryotherapeutics
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
To the complete profileof Synendos Therapeuthics
Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to …
To the complete profileof Resolve Biosciences
Exit
Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic …
To the complete profileof Amal Therapeutics
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Our G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only …
To the complete profileof Akribion Therapeutics
GS Bavaria is the world‘s first supplier of nano- hard metal materials on industrial scale. Production is extremely cost-efficient, sustainable and comes with minimal energy consumption through our unique bioleaching …
To the complete profileof GS Bavaria
Exit
c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …
To the complete profileof c-LEcta
DyNAbind is offering innovative drug discovery products and services based on its proprietary Dynamic DNA-Encoded Library (D-DEL) technology platform. With D-DEL, DyNAbind can simultaneously screen hundreds of millions of compounds …
To the complete profileof DyNAbind
Exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
To the complete profileof Emergence Therapeutics
IOP GmbH will initiate a paradigm chance in glaucoma therapy by its products for telemetric, 24 hour monitoring of intraocular pressure, allowing personalized patient management.
To the complete profileof Implandata Ophthalmic Products
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. …
To the complete profileof NUMAFERM